Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS

Journal of the American Academy of Dermatology

Volumn 74, Issue 5, 2016, Pages 974-980

  Gallitano, Stephanie M ^a   McDermott, Laura ^a   Brar, Kanwaljit ^b   Lowenstein, Eve ^a  

^a SUNY Downstate Medical Center   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

AIDS; autoimmune disease; hidradenitis suppurativa; HIV; inflammatory bowel disease; opportunistic infections; psoriasis; rheumatoid arthritis; tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CD4+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; FEMALE; HIV INFECTIONS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CD4-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; ETANERCEPT; FEMALE; HIV INFECTIONS; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; QUALITY IMPROVEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84954270938     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.11.043     Document Type: Review

References (33)

1. P.P. Kaur, V.C. Chan, and S.N. Berney Successful etanercept use in an HIV-positive patient with rheumatoid arthritis J Clin Rheumatol 13 2 2007 79 80
2. L.H. Calabrese, N. Zein, and D. Vassilopoulos Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection Ann Rheum Dis 63 Suppl 2 2004 ii18 ii24
3. F. Cedeno-Laurent, M. Gómez-Flores, N. Mendez, and et al. New insights into HIV-1-primary skin disorders J Int AIDS Soc 14 2011 5
4. N. Morar, S.A. Willis-Owen, T. Maurer, and C.B. Bunker HIV-associated psoriasis: pathogenesis, clinical features, and management Lancet Infect Dis 10 7 2010 470 478
5. R.S. Wallis, P. Kyambadde, J.L. Johnson, and et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis AIDS 18 2 2004 257 264
6. S.F. Lindsey, J. Weiss, E.S. Lee, and P. Romanelli Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient J Drugs Dermatol 13 7 2014 869 871
7. J. Sellam, B. Bouvard, C. Masson, and et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients Joint Bone Spine 74 2 2007 197 200
8. L. Osborn, S. Kunkel, and G.J. Nabel Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B Proc Natl Acad Sci USA 86 7 1989 2336 2340
9. N.I. Wada, L.P. Jacobson, J.B. Margolick, and et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation AIDS 29 4 2015 463 471
10. E. Ledru, N. Christeff, O. Patey, and et al. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome Blood 95 10 2000 3191 3198
11. A. Kumar, W. Abbas, and G. Herbein TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators Inflamm 2013 2013 484378
12. R.E. Walker, K.M. Spooner, G. Kelly, and et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1 J Infect Dis 174 1 1996 63 68
13. B.E. Sha, H. Valdez, R.S. Gelman, and et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2 AIDS Res Hum Retroviruses 18 9 2002 661 665
14. J.J. Emer Is there a potential role for anti-tumor necrosis factor therapy in patients with human immunodeficiency virus? J Clin Aesthet Dermatol 2 4 2009 29 35
15. P.T. Ting, and J.Y. Koo Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients Int J Dermatol 45 6 2006 689 692
16. M.J. Shale, C.H. Seow, C.S. Coffin, and et al. Review article: chronic viral infection in the anti-tumor necrosis factor therapy era in inflammatory bowel disease Aliment Pharmacol Ther 31 1 2010 20 34
17. R.S. Wallis, M. Broder, J. Wong, and et al. Granulomatous infections due to tumor necrosis factor blockade: correction Clin Infect Dis 39 8 2004 1254 1255
18. D.M. Aboulafia, D. Bundow, K. Wilske, and et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis Mayo Clin Proc 75 10 2000 1093 1098
19. N. Gaylis Infliximab in the treatment of an HIV positive patient with Reiter's syndrome J Rheumatol 30 2 2003 407 411
20. N.B. Gaylis Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab J Clin Rheumatol 18 3 2012 153 154
21. U. Bartke, I. Venten, A. Kreuter, and et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab Br J Dermatol 150 4 2004 784 786
22. + T-cell loss related to apoptosis Arch Intern Med 166 16 2006 1783 1784
23. B. Beltrán, P. Nos, G. Bastida, and et al. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease Gut 55 11 2006 1670 1671
24. G. Linardaki, O. Katsarou, P. Ioannidou, and et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection J Rheumatol 34 6 2007 1353 1355
25. E.J. Cepeda, F.M. Williams, M.L. Ishimori, and et al. The use of anti-tumor necrosis factor therapy in HIV-positive individuals with rheumatic disease Ann Rheum Dis 67 5 2008 710 712
26. M. Mikhail, J.M. Weinberg, and B.L. Smith Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus Arch Dermatol 144 4 2008 453 456
27. S. Carrión, E. Domènech, and J. Romeu Pulmonary and nodal tuberculosis in a patient with inflammatory bowel disease and HIV infection treated with infliximab J Crohns Colitis 3 3 2009 220 221
28. D. Alecsandru, B. Padilla, J.A. Izquierdo, and et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab Arch Dermatol 146 12 2010 1343 1345
29. H. Husein-ElAhmed, M.A. Fernandez-Pugnaire, and J.C. Ruiz-Carrascosa Severe hidradenitis suppurative in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade AIDS Patient Care STDS 25 9 2011 507 508
30. H. Almoallim, I. Jali, and G. Wali Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia Joint Bone Spine 80 4 2013 426 428
31. V. Di Lernia, G. Zoboli, and E. Ficarelli Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept Indian J Dermatol Venereol Leprol 79 3 2013 444
32. P. De Nardo, R. Bellagamba, A. Corpolongo, and et al. Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report Clin Vaccine Immunol 20 5 2013 761 764
33. K. Menon, A.S. Van Voorhees, B.F. Bebo, and et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation J Am Acad Dermatol 62 2 2010 291 299